Antithrombin Market|Grifols, Shire Plc., rEVO Biologics Inc., CSL Limited, Kedrion S.p.A,
Antithrombin is a blood protein that prevents blood clotting by inactivating the enzyme thrombin. Antithrombin is a 432 amino acid protein generated by the liver. Acquired antithrombin deficiency, which is caused by various disorders such nephrotic syndrome, liver failure, severe trauma, and metastatic cancers, and hereditary antithrombin deficiency, which is caused by a genetic mutation or aberration, are the two main causes of antithrombin deficiency. Inherited antithrombin deficiency is a rare condition, with about 0.2 percent of the global population suffering from it, according to the NCBI (National Center for Biotechnology Information). ATryn, which was created by rEVO Biologics and acquired the U.S. Food and Drug Administration's approval, is one of the most popular antithrombin deficiency medications on the market. In 2009, the Food and Drug Administration (FDA) granted approval. Antithrombin and heparin have a synergistic effect, enhancing antithrombin binding to Throm...